Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters.
Publication/Presentation Date
9-1-2019
Abstract
Engraftment syndrome (ES) is a known complication of autologous hematopoietic stem cell transplant during neutrophil recovery. There is a limited amount of data available comparing the incidence of ES with post-transplant granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor (GM-CSF), specifically in patients with multiple myeloma. Our retrospective review of 156 patients at a single center showed that GM-CSF was associated with a higher incidence of ES compared with G-CSF (32% versus 8% of patients, P < .001) and that development of ES was associated with a 32.9% (P < .001) longer hospital stay. This suggests that the choice of growth factor could possibly contribute to the development of ES and the associated costs of increased medical care.
Volume
25
Issue
9
First Page
293
Last Page
293
ISSN
1523-6536
Published In/Presented At
Chen, J., Pan, J., Zhan, T., Tuazon, S., Saini, N., O'Hara, W., Filicko-O'Hara, J., Klumpp, T., Kasner, M., Carabasi, M., Porcu, P., & Wagner, J. L. (2019). Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25(9), e293–e297. https://doi.org/10.1016/j.bbmt.2019.05.035
Disciplines
Medicine and Health Sciences
PubMedID
31173899
Department(s)
Hematology-Medical Oncology Division
Document Type
Article